Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thermosensitive Gel Nasal Spray with Exosomes, Mupirocin, and DNase I for Chronic Rhinosinusitis
NCT07635433Phase 1Not yet recruiting
- Sponsor
- Xinxiang Medical University First Affiliated Hospital
- Start
- Jul 2026
- Primary completion
- Jun 2027
01
Overview
Phase 1, randomised, double-blind trial of human umbilical cord mesenchymal stem cell-derived exosomes in chronic rhinosinusitis (CRS) (3 arms), sponsored by Xinxiang Medical University First Affiliated Hospital. Primary endpoint: Number of Participants with Treatment-Related Adverse Events at Day 90. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cell-derived exosomes
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT07635433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07635433.